Rutgers research partner Stemcyte, Inc., expands to New Jersey

Collaborative research environment triggers move of umbilical cord stem cell company

NEW BRUNSWICK, N.J. – Officials from Rutgers University and state government today welcomed StemCyte, Inc., to the Garden State. One of the factors in the company’s decision to move into New Jersey was a desire to be closer to Rutgers and the groundbreaking research taking place at the university.

StemCyte’s new office in Ewing Township will house members of its executive management and therapeutics team, establishing a base of operations for the company’s northeast United States therapeutics program. StemCyte is a global umbilical cord blood (UCB) stem cell and therapeutic products company.

Rutgers and StemCyte have been collaborating on a spinal cord injury therapy in development by Dr. Wise Young, the Richard H. Shindell Professor of Neuroscience. Young’s therapy, which uses StemCyte’s proprietary human UCB stem cells in conjunction with lithium, is undergoing clinical trials in China in a network of medical facilities brought together by Young.

“I am proud of New Jersey's and Rutger's commitment to stem cell therapeutics,” Young said. “StemCyte is the only company today that is actually curing hundreds of people with stem cells.” Over the past six years, StemCyte has treated patients with 35 types of diseases in 32 countries with a UCB stem cell product.

“The synergy emanating from this partnership of academia and industry is already global in its scope,” said Richard L. McCormick, president of Rutgers, The State University of New Jersey. “Dr. Young’s work with people in China offers new hope to spinal cord injury patients and their families here in New Jersey and worldwide. We are pleased to welcome StemCyte as new neighbors in a statewide community that is focused on medical progress.”